Chidamide and Anlotinib act synergistically in Jurkat cells by inhibiting the Hippo signaling pathway
Background: T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive hematologic malignancy characterized by drug resistance, relapse and poor prognosis. Chidamide, a histone deacetylase inhibitor, has shown epigenetic therapeutic potential in T-ALL, but its efficacy is limited and acquired drug...
Збережено в:
| Автори: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Elsevier
2026-03-01
|
| Серія: | Biochemistry and Biophysics Reports |
| Предмети: | |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S2405580826000294 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|